Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-α versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial)
- Patel, V. C. (Speaker)
Activity: Talk or presentation › Oral presentation